Granted Patent B2

US 12,220,560 · App. 17/819,171 · Granted Feb 11, 2025

Inventors: Thomas Kramer (Andover, MN); Matthew H. Rust (Hudson, WI); Paul M. Goudreau (St. Paul, MN); Peter A Hoeft (Seattle, WA); Julius C. Sund (Plymouth, MN); Peter L. Sadowski (Woodbury, MN); Michael Travanty (S. Minneapolis, MN); Patrick Madsen (Litchfield, MN)

Assignee: Antares Pharma, Inc.

A61M5/2033A61M5/20A61M5/2053A61M5/30A61M5/5086A61M2005/2013A61M2005/2026A61M2005/208A61M2005/3125A61M5/326A61M2202/0007A61M2202/048

Abstract

Claims (32)

1. An injector, comprising:

a housing extending along a longitudinal axis;

a medicament container disposed within the housing and containing a volume of a medicament;

a trigger mechanism including:

a floating trigger member rotatable about the longitudinal axis between a pre-firing condition and a firing condition and having a retaining portion, and

a ram assembly having a ram configured to pressurize the medicament container for expelling the medicament therefrom and a floating trigger engagement member configured to engage the retaining portion of the floating trigger member when the floating trigger member is in the pre-firing condition;

an energy source associated with the ram configured to move the ram relative to the medicament container to expel the medicament; and

a user-operable firing-initiation member configured to move the floating trigger member from the pre-firing condition to the firing condition where the floating trigger engagement member is released from the retaining portion to allow the energy source to fire the ram,

wherein the energy source is coupled to the housing and decoupled from the user-operable firing-initiation member.

2. The injector of claim 1 , wherein the firing-initiation member includes a skin-contacting member disposed at a distal end of the injector that is moveable proximally with respect to the housing when a force is applied to the skin-contacting member at the distal end of the injector, the firing-initiation member being associated with the floating trigger member and configured to cause the axial rotation of the floating trigger member from the pre-firing condition to the firing condition upon a proximal movement of the skin-contacting member with respect to the housing.

3. The injector of claim 2 , wherein the skin-contacting member includes a needle guard that is retractable and is configured to expose the needle upon the proximal movement of the skin-contacting member.

4. The injector of claim 3 , wherein the needle is in fluid communication with the medicament container for injecting the medicament expelled therefrom during a firing.

5. The injector of claim 3 , wherein the energy source and the needle are configured for jet injecting the medicament through the needle.

6. The injector of claim 5 , wherein the energy source is configured to pressurize the medicament to between about 90 psi and about 500 psi to jet inject the medicament.

7. The injector of claim 5 , wherein the energy source and the needle are configured for injecting the medicament at an average velocity of at least about 1,000 cm/see within the needle.

8. The injector of claim 2 , wherein the skin-contacting member comprises a first cam, and the floating trigger member comprises a second cam, the first cam being operatively associated with the second cam so as to cause axial rotation of the floating trigger member from the pre-firing condition to the firing condition upon proximal movement of the skin-contacting member with respect to the housing.

9. The injector of claim 1 , further comprising an end cap, said end cap comprising a ram holding member that axially retains the ram assembly in a proximal position against action of the energy source when the floating trigger member is in the pre-firing condition, the retaining portion retaining the floating trigger engagement member engaged and held against the firing by the ram holding member.

10. The injector of claim 9 , wherein when the floating trigger member is in the firing condition, the ram is disengaged from the retaining portion, and the energy source overcomes an engagement between the floating trigger engagement member and the ram holding member.

11. The injector of claim 9 , wherein the ram holding member includes a projection that includes a bulge and a groove engaged with the floating trigger engagement member, and the retaining portion retains the engagement of the floating trigger engagement member with the bulge and the groove when the floating trigger member is in the pre-firing condition.

12. The injector of claim 1 , wherein the ram assembly is of unitary construction.

13. The injector of claim 1 , further comprising a container support that is configured for holding the medicament container during injection, wherein the ram assembly is configured to engage the container support to lock-out the injector after an injection.

14. The injector of claim 13 , wherein proximal movement of the user-operable firing-initiation member is blocked by the ram assembly when the injector is locked-out.

15. The injector of claim 1 , wherein the pre-firing color gamut is visible from an exterior of the injector when the floating trigger member is in the pre-firing condition, the injector further comprising:

a housing including a window; and

an indicator having an indicator color that is absent from the pre-firing color gamut, which color is hidden from view within the housing in the pre-firing condition, wherein when the floating trigger member is in the firing condition, the indicator color is visible through the window from an exterior of the injector for indicating the firing condition.

16. The injector of claim 15 , wherein the ram assembly includes the indicator.

17. The injector of claim 16 , wherein the ram assembly entirely occludes the window in the firing condition.

18. The injector of claim 1 , wherein the medicament comprises an androgen.

19. The injector of claim 18 , wherein the androgen includes testosterone or a derivative or ester thereof.

20. The injector of claim 19 , wherein the androgen includes testosterone cypionate.

21. The injector of claim 19 , wherein the androgen includes testosterone enanthate.

22. The injector of claim 1 , wherein the medicament comprises a midazolam.

Assignments (1)

Continuity (8)

References Cited (400)